Targeting eicosanoid pathways in the development of novel anti-influenza drugs

References

• Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48(8):1003-32
   PubMed Web of Science ®Google Scholar
• Peaper DR, Landry ML. Rapid diagnosis of influenza: state of the art. Clin Lab Med 2014;34(2):365-85
   PubMed Web of Science ®Google Scholar
• Donaldson L. A pandemic on the horizon. J Royal Soc Med 2006;99(5):222-5
   PubMedGoogle Scholar
• Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545
   PubMed Web of Science ®Google Scholar
• Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2547
   PubMedGoogle Scholar
• Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009;361(23):2296-7
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178(5):1257-62
   PubMedGoogle Scholar
• Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009;48(4):389-96
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res 2013;100(2):446-54
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol 2012;12(4):295-305
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014;14(5):315-28
   PubMed Web of Science ®Google Scholar
• Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 2007;8(11):1188-93
   PubMed Web of Science ®Google Scholar
• van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 2012;4(9):1438-76
   PubMed Web of Science ®Google Scholar
• Chakrabarti AK, Pasricha G. An insight into the PB1F2 protein and its multifunctional role in enhancing the pathogenicity of the influenza A viruses. Virology 2013;440(2):97-104
   PubMedGoogle Scholar
• Mora R, Rodriguez-Boulan E, Palese P, Garcia-Sastre A. Apical budding of a recombinant influenza A virus expressing a hemagglutinin protein with a basolateral localization signal. J Virol 2002;76(7):3544-53
   PubMedGoogle Scholar
• Coulombe F, Jaworska J, Verway M, et al. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014;40(4):554-68
   PubMed Web of Science ®Google Scholar
• Schneider C, Nobs SP, Heer AK, et al. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. PLoS Pathog 2014;10(4):e1004053
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee YW, Lee KJ, et al. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol 2008;82(9):4265-74
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Takeuchi O, Kato H, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 2007;27(2):240-52
   PubMedGoogle Scholar
• Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014;14(2):81-93
   PubMed Web of Science ®Google Scholar
• Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008;14(10):461-9
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31(5):986-1000
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005;174(2):589-94
   PubMedGoogle Scholar
• Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014;40(3):315-27
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971;231(25):237-9
   PubMedGoogle Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232-5
   PubMedGoogle Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11(2):81s-110s
   PubMed Web of Science ®Google Scholar
• Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165(2):171-7
   PubMedGoogle Scholar
• Starko KM. Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence. Clin Infect Dis 2009;49(9):1405-10
   PubMedGoogle Scholar
• Starko KM, Ray CG, Dominguez LB, et al. Reye’s syndrome and salicylate use. Pediatrics 1980;66(6):859-64
   PubMed Web of Science ®Google Scholar
• Lee SM, Cheung CY, Nicholls JM, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008;198(4):525-35
   PubMedGoogle Scholar
• Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antivir Res 2011;91(3):330-4
   PubMedGoogle Scholar
• Steer SA, Moran JM, Maggi LB Jr, et al. Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection. J Immunol 2003;170(2):1070-6
   PubMedGoogle Scholar
• Carey MA, Bradbury JA, Seubert JM, et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005;175(10):6878-84
   PubMedGoogle Scholar
• Hodges RJ, Jenkins RG, Wheeler-Jones CP, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 2004;165(5):1663-76
   PubMedGoogle Scholar
• Lauder SN, Taylor PR, Clark SR, et al. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 2011;66(5):368-74
   PubMed Web of Science ®Google Scholar
• Carey MA, Bradbury JA, Rebolloso YD, et al. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 2010;5(7):e11610
   PubMed Web of Science ®Google Scholar
• Brenneis C, Maier TJ, Schmidt R, et al. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J 2006;20(9):1352-60
   PubMedGoogle Scholar
• Xu D, Rowland SE, Clark P, et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008;326(3):754-63
   PubMed Web of Science ®Google Scholar
• Cloutier A, Marois I, Cloutier D, et al. The prostanoid 15-deoxy-Delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J Infect Dis 2012;205(4):621-30
   PubMedGoogle Scholar
• Abdel-Tawab M, Zettl H, Schubert-Zsilavecz M. Nonsteroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem 2009;16(16):2042-63
   PubMedGoogle Scholar
• Korotkova M, Jakobsson PJ. Microsomal prostaglandin e synthase-1 in rheumatic diseases. Front Pharmacol 2010;1:146
   PubMedGoogle Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Investig 2006;116(5):1391-9
   PubMed Web of Science ®Google Scholar
• Wu D, Mennerich D, Arndt K, et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat 2009;90(1-2):21-5
   PubMedGoogle Scholar
• Bylund J, Annas A, Hellgren D, et al. Amide hydrolysis of a novel chemical series of microsomal prostaglandin E synthase-1 inhibitors induces kidney toxicity in the rat. Drug Metab Dispos 2013;41(3):634-41
   PubMedGoogle Scholar
• Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-14
   PubMedGoogle Scholar
• Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008;105(23):8091-6
   PubMed Web of Science ®Google Scholar
• Gaudreault E, Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol 2008;180(9):6211-21
   PubMedGoogle Scholar
• Morita M, Kuba K, Ichikawa A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013;153(1):112-25
   PubMed Web of Science ®Google Scholar